Clinical Trial Update: Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics study of NEX-22A in adults with Type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NEX-22A (NEX-22A)

Snippet

Sponsor: Nanexa AB | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED